A Phase 3 interventional study of PD-0332991 and Letrozole in Breast Neoplasms, sponsored by Pfizer. Completed at 305 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 4 that started in 2013, is one of 20 in phase 3, and was the 8th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18+
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 666 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 9th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2013, is one of 25 in phase 3, and was the 69th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Drug: PD-0332991 · Drug: Letrozole
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Drug: Placebo · Drug: Letrozole
PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Letrozole, 2.5mg, orally once daily (continuously)
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Letrozole, 2.5mg, orally once daily (continuously)
Progression-Free Survival (PFS) as Assessed by the Investigator
PFS is defined as the time from the date of randomization to the date of the first documentation of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death due to any cause in the absence of documented PD, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date - randomization date +1)/30.4. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions, or the appearance of new lesions.
Time frame: From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)
Objective Response as Assessed by the Investigator
Objective Response (OR) defined as overall complete response (CR) or partial response (PR) according to RECIST v1.1. Objective Response Rate (ORR) is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
Time frame: From randomization until end of treatment (up to approximately 2.5 years)
Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator
The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
Time frame: From randomization until end of treatment (up to approximately 2.5 years)
Duration of Response (DR)
DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as \[the date response ended (i.e. date of PD or death) - first CR or PR date + 1)\]/30.4. DR would only be calculated for the subgroup of participants with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
Time frame: From randomization until end of treatment (up to approximately 2.5 years)
Disease Control (DC)/Clinical Benefit Response (CBR)
DC is defined as overall CR, PR, or stable disease (SD) \>=24 weeks according to RECIST version 1.1. Disease Control Rate (DCR) is defined as participants with CR, PR, or SD \>=24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD\>=24 weeks, or who died, progressed, or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD\>=24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression.
Time frame: From randomization until end of treatment (up to approximately 2.5 years)
PFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)
PFS by biomarker status by Investigator assessment. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Positive is defined as H-Score \>=1 and negative as H-Score \<1. H-Score is calculated as the sum of the % of cells at each level of staining intensity (0, 1+, 2+, and 3+) multiplied by the staining intensity value: H-Score = (% at 0)\*0 + (% at 1+)\*1 + (% at 2+)\*2 + (% at 3+)\*3. H-Score values range from 0 to 300. ER stands for estrogen receptor and Rb stands for retinoblastoma susceptibility gene product.
Time frame: From randomization until end of treatment (up to approximately 24 Months)
Corrected QT Interval (QTc) Time-Matched Change From Baseline on Cycle 1 Day 14
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Time-matched change from baseline values were reported for QTc analysis population.
Time frame: Time-matched triplicate ECGs were collected at 0 (predose), 2, 4, 6 and 8 hours on Day 0 and on Cycle1 Day14
Percentage of Participants With Corrected QT Interval (QTc)
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Percentage of participants with post-baseline maximum absolute values and maximum increase from baseline were summarized for the safety analysis population.
Time frame: For safety monitoring triplicate ECGs were obtained at 0 hour (pre-dose) on Day 1 of Cycle 1, Day 14 of Cycles 1 and Cycle 2, then on Day 1 of Cycles 4, 7, and 10 (ECGs beyond Cycle 10 were performed as clinically indicated)
Observed Plasma Trough Concentration (Ctrough) at Steady-State
Summary of plasma palbociclib within-participant mean steady-state trough concentrations.
Time frame: 0 hour (predose) on Day 14 of cycles 1 and 2
Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index
The EuroQol EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (1=no problem, 2=some problem, and 3=extreme problem). The scores on the 5 descriptors are summarized to create a single summary score. An overall utility score is calculated based on these domains, with a range score from 0 (worse health scenario) to a maximum of 1.0 (best health scenario).
Time frame: From Baseline up to 2.5 years
Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)
FACT is a modular approach to assess participant health-related quality of life using a 'core' set of questions (FACT-G) as well as a cancer site-specific module. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. The FACT-B consisted of the FACT-G (27-item) and a breast-specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a five-level scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. FACT-B total score = Physical Well-Being + Social/Family Well-Being + Emotional Well-Being + Functional Well-Being + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-144, with 0 being the worst possible score and 144 the best.
Time frame: From Baseline up to 2.5 years
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs): All Causalities
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization; resulted in persistent or significant disability or in congenital anomaly/birth defect. TEAE were events that occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Severity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening and Grade 5 = death related to AE. Discontinuation included permanent, temporary discontinuation and dose reduction due to AEs.
Time frame: From date of randomization up to 28 days after last dose of study drug (final analysis till study completion, approximately up to 10.51 years)
Overall Survival (OS): Primary Analysis
OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at primary analysis.
Time frame: From date of randomization until death due to any cause or censored, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
Overall Survival (OS): Final Analysis
OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at final analysis.
Time frame: From date of randomization until death due to any cause or censored (final analysis till study completion, approximately up to 10.51 years)
Survival Probability at 1 Year, 2 Year and 3 Year
One, two or three-year survival probability was defined as the probability of survival 1 year, 2 or 3 years after the date of randomization. The survival probability was estimated using the Kaplan-Meier method and 2-sided 95% confidence interval (CI) was calculated using the product limit method.
Time frame: 1, 2 and 3 years after randomization
Number of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade
Laboratory abnormalities included anemia, hemoglobin increased, neutrophils (absolute), platelets, white blood cells, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia and hyponatremia. Laboratory abnormalities were graded by CTCAE version (v) 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life-threatening. Categories with at least 1 non-zero data values are reported.
Time frame: From randomization up to 28 days after last dose of study drug (assessed up to analysis date of 15-Nov-2021, approximately 8.7 years)
A total of 666 participants were randomized at 239 centers in 19 countries.
| Milestone | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Started | 444 | 222 |
| Completed | 0 | 0 |
| Not completed | 444 | 222 |
| Withdrew: Objective progression or relapse | 286 | 172 |
| Withdrew: Adverse event | 32 | 9 |
| Withdrew: Global deterioration of health status | 28 | 12 |
| Withdrew: Participant refused continued treatment | 27 | 15 |
| Withdrew: Unspecified reasons | 52 | 8 |
| Withdrew: Death | 10 | 3 |
| Withdrew: Protocol violation | 5 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Site terminated by sponsor | 1 | 0 |
PFS is defined as the time from the date of randomization to the date of the first documentation of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death due to any cause in the absence of documented PD, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date - randomization date +1)/30.4. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions, or the appearance of new lesions.
| Months | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by the Investigator | 24.8 (22.1 to NA) | 14.5 (12.9 to 17.1) |
Objective Response (OR) defined as overall complete response (CR) or partial response (PR) according to RECIST v1.1. Objective Response Rate (ORR) is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
| Percentage of participants | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Objective Response as Assessed by the Investigator | 46.4 (41.7 to 51.2) | 38.3 (31.9 to 45.0) |
The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
| Percentage of participants | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator | 60.7 (55.2 to 65.9) | 49.1 (41.4 to 56.9) |
DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as \[the date response ended (i.e. date of PD or death) - first CR or PR date + 1)\]/30.4. DR would only be calculated for the subgroup of participants with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
| Months | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Duration of Response (DR) | 20.1 (19.3 to 28.0) | 16.7 (13.8 to 22.5) |
DC is defined as overall CR, PR, or stable disease (SD) \>=24 weeks according to RECIST version 1.1. Disease Control Rate (DCR) is defined as participants with CR, PR, or SD \>=24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD\>=24 weeks, or who died, progressed, or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD\>=24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression.
| Percentage of participants | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Disease Control (DC)/Clinical Benefit Response (CBR) | 85.8 (82.2 to 88.9) | 71.2 (64.7 to 77.0) |
PFS by biomarker status by Investigator assessment. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Positive is defined as H-Score \>=1 and negative as H-Score \<1. H-Score is calculated as the sum of the % of cells at each level of staining intensity (0, 1+, 2+, and 3+) multiplied by the staining intensity value: H-Score = (% at 0)\*0 + (% at 1+)\*1 + (% at 2+)\*2 + (% at 3+)\*3. H-Score values range from 0 to 300. ER stands for estrogen receptor and Rb stands for retinoblastoma susceptibility gene product.
| Months | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| ER Positive | 24.9 (22.2 to NA) | 16.3 (12.9 to 19.1) |
| ER Negative | 15.6 (8.3 to 22.0) | 5.4 (2.7 to 11.1) |
| Rb Positive | 24.2 (21.4 to 25.7) | 13.7 (11.0 to 16.5) |
| Rb Negative | NA (11.4 to NA) | 18.5 (2.9 to NA) |
| Cyclin D1 Positive | 24.8 (21.5 to 27.6) | 13.8 (11.3 to 16.8) |
| Cyclin D1 Negative | 11.1 (2.2 to 23.9) | 8.1 (0.4 to NA) |
| p16 Positive | 24.8 (21.5 to NA) | 13.8 (11.1 to 16.8) |
| p16 Negative | 16.8 (11.1 to 24.9) | 13.8 (8.1 to NA) |
| p16 H-Score<175 | 23.7 (19.6 to 25.7) | 13.8 (11.2 to 16.8) |
| p16 H-Score>=175 | 24.2 (11.1 to NA) | 5.6 (1.5 to 19.1) |
| Ki67 <=20% | 27.6 (24.2 to NA) | 16.8 (13.7 to 22.0) |
| Ki67 >20% | 17.5 (13.8 to 22.0) | 8.4 (5.6 to 13.6) |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Time-matched change from baseline values were reported for QTc analysis population.
| msec | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| QTcS at 0 hour | 0.80 (-1.67 to 3.26) | 2.95 (-0.19 to 6.10) |
| QTcS at 2 hour | 3.32 (0.79 to 5.85) | 1.65 (-1.48 to 4.78) |
| QTcS at 4 hour | 2.76 (0.23 to 5.30) | 1.74 (-1.39 to 4.87) |
| QTcS at 6 hour | 4.49 (1.96 to 7.02) | 0.72 (-2.41 to 3.85) |
| QTcS at 8 hour | 0.94 (-1.60 to 3.48) | 3.14 (0.01 to 6.27) |
| QTcF at 0 hour | 1.10 (-1.39 to 3.58) | 3.06 (-0.11 to 6.23) |
| QTcF at 2 hour | 3.68 (1.12 to 6.23) | 1.73 (-1.43 to 4.88) |
| QTcF at 4 hour | 2.86 (0.31 to 5.41) | 1.54 (-1.62 to 4.70) |
| QTcF at 6 hour | 4.57 (2.01 to 7.12) | 0.71 (-2.44 to 3.87) |
| QTcF at 8 hour | 1.21 (-1.36 to 3.77) | 2.84 (-0.31 to 6.00) |
| QTcB at 0 hour | -0.11 (-2.83 to 2.61) | 2.78 (-0.69 to 6.25) |
| QTcB at 2 hour | 1.46 (-1.34 to 4.25) | 0.83 (-2.63 to 4.28) |
| QTcB at 4 hour | 2.58 (-0.22 to 5.38) | 2.47 (-0.98 to 5.92) |
| QTcB at 6 hour | 4.03 (1.24 to 6.83) | 0.53 (-2.92 to 3.99) |
| QTcB at 8 hour | -0.17 (-2.98 to 2.64) | 4.14 (0.69 to 7.59) |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Percentage of participants with post-baseline maximum absolute values and maximum increase from baseline were summarized for the safety analysis population.
| Percentage of participants | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Maximum QTcS <450 msec | 80.5 | 85.9 |
| Maximum QTcS 450-<480 msec | 17.9 | 11.8 |
| Maximum QTcS 480-<500 msec | 1.1 | 2.3 |
| Maximum QTcS >=500 msec | 0.5 | 0 |
| Maximum QTcF <450 msec | 85.9 | 89.5 |
| Maximum QTcF 450-<480 msec | 12.2 | 9.5 |
| Maximum QTcF 480-<500 msec | 1.6 | 0.9 |
| Maximum QTcF >=500 msec | 0.2 | 0 |
| Maximum QTcB <450 msec | 64.9 | 69.1 |
| Maximum QTcB 450-<480 msec | 32.2 | 27.3 |
| Maximum QTcB 480-<500 msec | 2.3 | 3.2 |
| Maximum QTcB >=500 msec | 0.7 | 0.5 |
| Maximum QTcS Change <30 msec | 92.7 | 94.5 |
| Maximum QTcS 30<=Change <60 msec | 6.6 | 5.5 |
| Maximum QTcS Change>=60 msec | 0.7 | 0 |
| Maximum QTcF Change <30 msec | 91.6 | 93.6 |
| Maximum QTcF 30<=Change <60 msec | 7.9 | 6.4 |
| Maximum QTcF Change>=60 msec | 0.5 | 0 |
| Maximum QTcB Change <30 msec | 88.9 | 91.4 |
| Maximum QTcB 30<=Change <60 msec | 10.2 | 8.2 |
| Maximum QTcB Change>=60 msec | 0.9 | 0.5 |
Summary of plasma palbociclib within-participant mean steady-state trough concentrations.
| Nanogram per milliliter (ng/mL) | Palbociclib Plus Letrozole |
|---|---|
| Cycle 1 Day 14 | 70.1 ± 59 |
| Cycle 2 Day 14 | 64.2 ± 82 |
The EuroQol EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (1=no problem, 2=some problem, and 3=extreme problem). The scores on the 5 descriptors are summarized to create a single summary score. An overall utility score is calculated based on these domains, with a range score from 0 (worse health scenario) to a maximum of 1.0 (best health scenario).
| Units on a scale | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index | 0.014 (0.00 to 0.03) | -0.010 (-0.03 to 0.01) |
FACT is a modular approach to assess participant health-related quality of life using a 'core' set of questions (FACT-G) as well as a cancer site-specific module. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. The FACT-B consisted of the FACT-G (27-item) and a breast-specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a five-level scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. FACT-B total score = Physical Well-Being + Social/Family Well-Being + Emotional Well-Being + Functional Well-Being + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-144, with 0 being the worst possible score and 144 the best.
| Units on a scale | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B) | -0.106 (-1.42 to 1.21) | 0.219 (-1.68 to 2.12) |
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization; resulted in persistent or significant disability or in congenital anomaly/birth defect. TEAE were events that occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Severity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening and Grade 5 = death related to AE. Discontinuation included permanent, temporary discontinuation and dose reduction due to AEs.
| Percentage of participants | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Participants with AEs | 99.1 | 96.4 |
| Participants with SAEs | 28.2 | 17.1 |
| Participants with Grade 3 or 4 AEs | 83.1 | 30.2 |
| Participants with Grade 5 AEs | 3.6 | 2.3 |
| Permanently discontinued study due to AEs | 4.1 | 2.3 |
| Permanently disc. palbociclib/placebo due to AEs | 14.4 | 6.3 |
| Permanently discontinued letrozole due to AEs | 9.2 | 5.9 |
| Temporarily disc. palbociclib/placebo due to AEs | 79.7 | 17.1 |
| Temporarily discontinued letrozole due to AEs | 23.0 | 11.3 |
| With palbociclib/placebo dose reduction due to AEs | 41.9 | 2.3 |
OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at primary analysis.
| Months | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Overall Survival (OS): Primary Analysis | 53.9 (49.8 to 60.8) | 51.2 (43.7 to 58.9) |
OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at final analysis.
| Months | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Overall Survival (OS): Final Analysis | 53.8 (49.8 to 59.2) | 49.8 (42.3 to 56.4) |
One, two or three-year survival probability was defined as the probability of survival 1 year, 2 or 3 years after the date of randomization. The survival probability was estimated using the Kaplan-Meier method and 2-sided 95% confidence interval (CI) was calculated using the product limit method.
| Percent probability | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| 1 year survival probability | 92.7 (89.8 to 94.7) | 94.9 (91.0 to 97.2) |
| 2 year survival probability | 78.4 (74.1 to 82.0) | 82.5 (76.6 to 87.0) |
| 3 year survival probability | 69.8 (65.1 to 73.9) | 65.0 (58.0 to 71.1) |
Laboratory abnormalities included anemia, hemoglobin increased, neutrophils (absolute), platelets, white blood cells, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia and hyponatremia. Laboratory abnormalities were graded by CTCAE version (v) 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life-threatening. Categories with at least 1 non-zero data values are reported.
| Participants | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| Anemia: Grade 1-2 | 328 | 90 |
| Anemia: Grade 3 | 30 | 6 |
| Hemoglobin Increased: Grade 1-2 | 14 | 25 |
| Hemoglobin Increased: Grade 3 | 1 | 0 |
| Neutrophils (Absolute): Grade 1-2 | 109 | 42 |
| Neutrophils (Absolute): Grade 3 | 254 | 2 |
| Neutrophils (Absolute): Grade 4 | 60 | 1 |
| Platelets: Grade 1-2 | 289 | 32 |
| Platelets: Grade 3 | 6 | 0 |
| Platelets: Grade 4 | 1 | 0 |
| White Blood Cells: Grade 1-2 | 248 | 57 |
| White Blood Cells: Grade 3 | 177 | 0 |
| White Blood Cells: Grade 4 | 6 | 0 |
| ALT: Grade 1-2 | 222 | 76 |
| ALT: Grade 3 | 16 | 0 |
| ALT: Grade 4 | 1 | 0 |
| Alkaline Phosphatase: Grade 1-2 | 174 | 95 |
| Alkaline Phosphatase: Grade 3 | 7 | 0 |
| AST: Grade 1-2 | 260 | 82 |
| AST: Grade 3 | 23 | 2 |
| Bilirubin (Total): Grade 1-2 | 33 | 11 |
| Bilirubin (Total): Grade 3 | 3 | 0 |
| Creatinine: Grade 1-2 | 418 | 201 |
| Creatinine: Grade 3 | 8 | 0 |
| Creatinine: Grade 4 | 2 | 0 |
| Hypercalcemia: Grade 1-2 | 111 | 54 |
| Hypercalcemia: Grade 3 | 1 | 2 |
| Hyperkalemia: Grade 1-2 | 118 | 51 |
| Hyperkalemia: Grade 3 | 6 | 1 |
| Hyperkalemia: Grade 4 | 2 | 0 |
| Hypermagnesemia: Grade 1-2 | 71 | 26 |
| Hypermagnesemia: Grade 3 | 9 | 6 |
| Hypermagnesemia: Grade 4 | 2 | 0 |
| Hypernatremia: Grade 1-2 | 94 | 35 |
| Hypernatremia: Grade 3 | 8 | 1 |
| Hypoalbuminemia: Grade 1-2 | 118 | 42 |
| Hypoalbuminemia: Grade 3 | 2 | 0 |
| Hypocalcemia: Grade 1-2 | 158 | 48 |
| Hypocalcemia: Grade 3 | 4 | 1 |
| Hypocalcemia: Grade 4 | 3 | 0 |
| Hypokalemia: Grade 1-2 | 105 | 32 |
| Hypokalemia: Grade 3 | 11 | 2 |
| Hypomagnesemia: Grade 1-2 | 127 | 41 |
| Hypomagnesemia: Grade 3 | 1 | 0 |
| Hypomagnesemia: Grade 4 | 2 | 0 |
| Hyponatremia: Grade 1-2 | 107 | 44 |
| Hyponatremia: Grade 3 | 11 | 4 |
Collected over From the date of randomization up to 28 days after last dose of study medication (final analysis till study completion, approximately up to 10.51 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palbociclib Plus Letrozole | 16/444 (3.6%) | 125/444 (28.2%) | 435/444 (98%) |
| Placebo Plus Letrozole | 6/222 (2.7%) | 38/222 (17.1%) | 209/222 (94.1%) |
| Event | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| PneumoniaInfections and infestations | 4/444 | 5/222 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/444 | 0/222 |
| Urinary tract infectionInfections and infestations | 6/444 | 0/222 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/444 | 3/222 |
| AnaemiaBlood and lymphatic system disorders | 5/444 | 0/222 |
| Acute kidney injuryRenal and urinary disorders | 5/444 | 0/222 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 5/444 | 1/222 |
| VomitingGastrointestinal disorders | 2/444 | 2/222 |
| Disease progressionGeneral disorders | 4/444 | 0/222 |
| PyrexiaGeneral disorders | 4/444 | 0/222 |
| Event | Palbociclib Plus Letrozole | Placebo Plus Letrozole |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 308/444 | 8/222 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 187/444 | 89/222 |
| FatigueGeneral disorders | 183/444 | 65/222 |
| NauseaGastrointestinal disorders | 169/444 | 59/222 |
| AlopeciaSkin and subcutaneous tissue disorders | 150/444 | 36/222 |
| Hot flushVascular disorders | 101/444 | 69/222 |
| DiarrhoeaGastrointestinal disorders | 136/444 | 51/222 |
| CoughRespiratory, thoracic and mediastinal disorders | 127/444 | 48/222 |
| AnaemiaBlood and lymphatic system disorders | 125/444 | 23/222 |
| HeadacheNervous system disorders | 109/444 | 62/222 |
The intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.
| Age, Continuous(Years) | Palbociclib Plus Letrozole | Placebo Plus Letrozole | Total |
|---|---|---|---|
| Mean | 61.7 ± 10.6 | 60.6 ± 11.2 | 61.3 ± 10.8 |
| Sex: Female, Male(Participants) | Palbociclib Plus Letrozole | Placebo Plus Letrozole | Total |
|---|---|---|---|
| Female | 444 | 222 | 666 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 305 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2013 to primary completion in Feb 2016, 36 months.
Results were first posted in Apr 2017, 1 year 2 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 36 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib